Expression of molecular markers of peripheral blood lymphocyte activation before and after eye-preserving treatment for choroidal melanomas of various stages
DOI:
https://doi.org/10.31288/oftalmolzh202533134Keywords:
choroid, immunology, radiotherapy, transpupillary thermotherapy, molecular markers, ophthalmic oncology, choroidal melanomaAbstract
Purpose: To assess the expression of molecular markers of peripheral blood lymphocyte activation (СD7+, CD54+, CD95+) before and after eye-preserving treatment for Т1 to Т3 choroidal melanoma (CM).
Material and Methods: Expression of molecular markers of peripheral blood lymphocyte activation (СD7+, CD54+, CD95+) was examined before and after eye-preserving treatment for Т1 to Т3 CM. The major study group (group 1) consisted of 25 patients (14 (56.0%) women and 11 (44.0%) men; mean age (standard deviation (SD)), 51.7 (16.6) years) who received the eye-preserving treatment (transpupillary thermotherapy (TTT (delivered using the developed methodology) combined with strontium-90/yttrium-90 (90Sr/90Y) brachytherapy (BT)) for moderate to large (T1-T3) CM (tumor base, 3.1 to 15 mm; tumor thickness, 3.1 to 9.0 mm). The control group (group 2) consisted of 16 patients (12 (75.0%) women and 4 (25.0%) men; mean age (SD), 55.4 (11.2) years) who received TTT only for small (T1) CM (tumor base, ≤ 12 mm; tumor thickness, ≤ 3 mm).
Results: The expression of markers CD7+, СD54+, and CD95+ before treatment for Т1-Т3 CM was higher than before treatment for small Т1 CM, but the difference was significant only for the absolute expression of CD7+ (р = 0.0008).
After TTT for small Т1 CM, a statistically significant increase was observed only in the absolute and percentage expression of CD7+ (р = 0.04 and р = 0.0000, respectively) and the absolute expression of FAS-ligand CD95+ (р = 0.05). Additionally, the level of СD54+ increased after treatment, but not significantly. Absolute expression levels of these molecular markers decreased after TTT plus BT, but not significantly. Additionally, the percentage expression of СD7+ decreased statistically significantly (р = 0.02), and the percentage expression of СD95+ decreased statistically insignificantly (р = 0.06). After eye-preserving treatment for CM, there were significant differences between the two groups in the absolute and percentage expression of FAS-ligand CD95+ (р = 0.003 and р = 0.000, respectively) and CD54+ (р = 0.03 and р = 0.000 respectively), with these levels being lower in group 1.
Conclusion: Expression of molecular markers of peripheral blood lymphocyte activation (СD7+, CD54+, CD95+) increased with tumor progression in patients with CM. The expression of the markers increased after TTT only for small Т1 CM, and decreased after TTT plus BT (90Sr/90Y) for Т1-Т3 CM, likely due to the effect of radiotherapy.
References
Berezhna NM. [Role of immune cells in tumor microenvironment. Interplay of immune cells with other mircoenvironmental components]. Onkologiia. 2009; 11(39): 6-17. Russian.
Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001 Jun;11(3):255-63. https://doi.org/10.1097/00008390-200106000-00007
Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 Jul 15;119(2):317-27. https://doi.org/10.1002/ijc.21775
Fidler IJ, Poste G. The "seed and soil" hypothesis revisited. Lancet Oncol. 2008 Aug;9(8):808. https://doi.org/10.1016/S1470-2045(08)70201-8
Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 2008 Mar 1;371(9614):771-83. https://doi.org/10.1016/S0140-6736(08)60241-X
Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011 Sep 1;71(17):5601-5. https://doi.org/10.1158/0008-5472.CAN-11-1316
Rabson A, Roitt IM, Delves PJ. Really essential medical immunology. Oxford: Blackwell Publishing Ltd; 2005.
Velychko LM. [Expression of molecular markers of lymphocyte activation in peripheral blood of patients with uveal melanoma with various efficacy of organ-preserving treatment]. Oftalmol Zh. 2013;5:9-13. Russian.
Poliakova SI, Velychko LN, Bogdanova AV, Tsukanova IV. [Comparison of expression of molecular markers of lymphocyte activation in peripheral blood of patients with small T1 choroidal melanoma and healthy controls]. Oftalmol Zh. 2017;1:25- 8. Russian. https://doi.org/10.31288/oftalmolzh201712528
Tsukanova IV, Poliakova SI, Velychko LN, Bogdanova AV. Changes in the expression of molecular markers of peripheral blood lymphocyte activation in patients with small (T1) choroidal melanoma after transpupillary thermotherapy. J Ophthalmol (Ukraine). 2019;5:27-29. https://doi.org/10.31288/oftalmolzh201952729
Information Bulletin No. 22, based on Pat. of Ukraine №102,890 issued 25.11.2015. Method for treatment of T1 choroidal melanoma. Authors: Pasyechnikova NV, Naumenko VO, Poliakova SI, Tsukanova IV. Owner: State Institution Filatov Institute of Eye Diseases and Tissue Therapy, NAMS of Ukraine. Ukrainian.
Gluzman DF, Skliarenko LM, Nadgornaia VA, Kriachok IA. [Immunocytochemistry in tumor diagnosis]. Kyiv: Morion; 2003. Russian.
Buiko AS, translator. [Choroidal melanoma classification]. Oftalmol Zh. 2010;(6):20-30.
Morsing SKH, Rademakers T, Brouns SLN, Stalborch ADV, Donners MMPC, van Buul JD. ADAM10-Mediated Cleavage of ICAM-1 Is Involved in Neutrophil Transendothelial Migration. Cells. 2021 Jan 25;10(2):232. doi: 10.3390/cells10020232. https://doi.org/10.3390/cells10020232
Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood. 2011 Dec 22;118(26):6743-51. https://doi.org/10.1182/blood-2011-07-343566
Abadier M, Haghayegh Jahromi N, Cardoso Alves L, Boscacci R, Vestweber D, et al. Cell surface levels of endothelial ICAM-1 influence the transcellular or paracellular T-cell diapedesis across the blood-brain barrier. Eur J Immunol. 2015 Apr;45(4):1043-58. https://doi.org/10.1002/eji.201445125
Smith JR, David LL, Appukuttan B, Wilmarth PA. Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs. Am J Ophthalmol. 2018 Sep;193:197-229. https://doi.org/10.1016/j.ajo.2018.03.020
Khramenko NI, Konovalova NV, Usov VY, Velychko LM, Bogdanova OV. Immunity status and expression of molecular markers (ICAM-1, CD5, CD25, CD95) on lymphocytes of patients with recurrent anterior uveitis complicated by macular edema. Graefes Arch Clin Exp Ophthalmol. 2023 May;261(5):1423-1431. https://doi.org/10.1007/s00417-022-05938-6
Khramenko NI, Konovalova NV, Usov VY, Velychko LM, Bogdanova OV. Immunity status and expression of molecular markers (ICAM-1, CD5, CD25, CD95) on lymphocytes of patients with recurrent anterior uveitis complicated by macular edema. Graefes Arch Clin Exp Ophthalmol. 2023 May;261(5):1423-1431. https://doi.org/10.1007/s00417-022-05938-6
Khramenko NI, Velychko LM, Konovalova NV, Bogdanova OV, Gheorghe LD, Bobescu DV. Features of hemodynamic and immunological parameters in patients with recurrent uveitis complicated by hypertension, Fuchs heterochromic uveitis and Posner-Schlossman syndrome. Rom J Ophthalmol. 2023 Jan-Mar;67(1):20-32. https://doi.org/10.22336/rjo.2023.5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Drumi D.A., Tsukanova I.V., Poliakova S.I., Velychko L.M., Makarova M.B., Bogdanova O.V.
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
.png)
